Drug companies want to end it. This is not a partisan issue. It is a math issue. And for the patients and communities we serve, it is a survival issue.
Ramachandran is an associate professor of pharmacy administration at the University of Mississippi School of Pharmacy. The 340B drug discount program requires manufacturers to sell drugs to safety-net ...
Tuesday’s bill gives powers to the Attorney General’s Office to further enforce state law that prohibits manufacturers from ...
Catholic healthcare was not started nor inspired from profit and loss statements or a desire to drive more shareholder value. Instead, through acts of mercy, women religious crossed oceans on ...
April 8 (Reuters) - AbbVie has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for ...
The secretary of Indiana’s Family and Social Services Administration wants to change how hospitals purchase discounted drugs ...
As Medicare's MFP program, launched January 1, 2026, takes effect under the Inflation Reduction Act's Drug Price Negotiation ...
Pharmaceutical companies are spending hundreds of millions lobbying elected officials to try and persuade them to gut the ...
Pharmacy benefit managers (PBMs) are now facing the same transparency and accountability requirements that employers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results